B. Riley began coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a report published on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $21.50 price objective on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a buy rating and issued a $33.00 price target (up previously from $18.00) on shares of TG Therapeutics in a report on Tuesday, November 14th. SunTrust Banks reaffirmed a buy rating and set a $28.00 target price on shares of TG Therapeutics in a report on Tuesday, October 3rd. BidaskClub raised TG Therapeutics from a sell rating to a hold rating in a report on Thursday, August 24th. Zacks Investment Research downgraded TG Therapeutics from a buy rating to a hold rating in a report on Friday, August 4th. Finally, ValuEngine downgraded TG Therapeutics from a hold rating to a sell rating in a report on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $26.25.
Shares of TG Therapeutics (NASDAQ TGTX) opened at $8.15 on Friday. TG Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. analysts anticipate that TG Therapeutics will post -1.86 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in TGTX. State Street Corp lifted its holdings in shares of TG Therapeutics by 274.4% during the second quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after purchasing an additional 1,933,896 shares during the period. Artal Group S.A. purchased a new position in TG Therapeutics during the second quarter valued at approximately $5,025,000. Franklin Resources Inc. raised its position in TG Therapeutics by 20.6% during the second quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock valued at $23,509,000 after acquiring an additional 398,916 shares in the last quarter. Columbus Circle Investors raised its position in TG Therapeutics by 39.0% during the second quarter. Columbus Circle Investors now owns 1,396,396 shares of the biopharmaceutical company’s stock valued at $14,034,000 after acquiring an additional 391,975 shares in the last quarter. Finally, Kennedy Capital Management Inc. raised its position in TG Therapeutics by 151.6% during the second quarter. Kennedy Capital Management Inc. now owns 565,178 shares of the biopharmaceutical company’s stock valued at $5,680,000 after acquiring an additional 340,545 shares in the last quarter. 50.45% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “TG Therapeutics (TGTX) Coverage Initiated by Analysts at B. Riley” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/05/tg-therapeutics-tgtx-coverage-initiated-by-analysts-at-b-riley.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.